PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-919

Resignation of Dr Richard Mollard27 May 2022 – Perth, AustraliaharmAust Limited (ASX: PAA & PAAO), a clinical-stage biotechnology company, advises that Chief Scientific Officer of PharmAust Ltd and Chief Executive Officer of PharmAust’s fully owned subsidiary Pitney Pharmaceuticals Pty Ltd, Dr Richard Mollard, has tendered his resignation and given the Company six months’ notice as required under his contract. Dr Mollard has been with PharmAust for five years and, during this time, he has played an important role in establishing and undertaking many activities on behalf of the Company.Executive Chairman Dr Roger Aston said: “We thank Richard for his efforts for us and wish him well in his future endeavours.” The Company will consider the optimal way to resource and undertake future steps in furtherance of the Company’s different projects, and this may include identifying several resources for the different projects.


Current projects are now established with Principle Investigators leading the research. As CSO, RM didn't work in a lab setting holding a test tube. He was the co-ordinator of the various projects. No cause for alarm.